Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus

Wu, Xing; Yu, Zhexin; Su, Wen; Isquith, Daniel; Neradilek, Moni B.; Lü, Ning; Gu, Fei; Li, Hongwei; Zhao, Xue-Qiao

doi:10.1016/j.jacl.2017.01.009

Cited by 30 publications

(24 citation statements)

References 36 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, we did not find any differences in HDL-c levels between patients with LDL-c within and above target. Low levels of ApoA1 also seem to independently associated with new T2DM (30). Nonetheless, according to the ESC/EAS guidelines, our patients evidenced normal ApoA1 concentrations and we did not find any differences in ApoA1 levels between patients with LDLc within and above target.…”

Section: Hdl-c and Apoa1mentioning

confidence: 40%

Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol

Fonseca

Paredes

Ramos

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: Lipid-lowering therapy is guided by Low-density-lipoprotein cholesterol (LDL-c), although the CVD risk could be better reflected by other lipid parameters. This study aimed the evaluation of a comprehensive lipid profile in patients with type 2 diabetes mellitus (T2DM) and comparation of those achieving and not achieving LDL-c control in respect to other non-conventional lipid parameters. Methods: We characterized a comprehensive lipid profile in 96 T2DM patients. ESC/EAS 2016 and 2019 Guidelines for the Management of Dyslipidemias were used to define LDL-c targets. Atherogenic lipoprotein profile was compared in patients with LDL-c within and above the target. Results: Only 28.1% and 16.7% of patients had mean LDL-c levels within the 2016 and 2019 guidelines, respectively. In patients with LDL-c within target by the 2016 guidelines, 22%, 25% and 44% presented levels above the recommended range for non-HDL-c, ApoB and oxidized LDL-c, respectively, whereas accordingly to the 2019 guidelines, 50%, 39% and 44% had elevated levels of -HDL-c, ApoB and oxidized LDL-c, respectively. There was a significant strong association of LDL-c and non-HDL-c (r=0.850), ApoB (r=0.656) and oxidized LDL-c (r=0.508). Similarly, non-HDL-c was significantly strongly correlated with ApoB (r=0.808) and oxidized LDL-c (r=0.588). Conclusions: These findings emphasize the limitations of a sole LDL-c measurement for CV risk assessment. Targeting only LDL-c could result in missed opportunities for CV risk reduction in T2DM individuals. Our data suggest that non-HDL-c, ApoB and oxidized LDL-c could be considered as part of these patients’ evaluation allowing a more accurate estimation of CV risk and treatment among these high-risk patients.

show abstract

Section: Hdl-c and Apoa1mentioning

confidence: 40%

Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol

Fonseca

Paredes

Ramos

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The results are in line with previous studies where a significant decline in Apo A1 levels was observed in diabetics as compared to control group. [25] In a recent study carried out by Wu et al (2017) diminution in Apo A1 individually led to a 97% increased risk of new T2DM over 4 years among urban Chinese community based population who were healthy and without any risk factor for T2DM. [10] However, in a Turkish sample population elevated Apo A1 levels individually predicted the incidence of T2DM with top tertile of serum Apo A1 approximately doubled the possibility of T2DM when compared with low tertile.…”

Section: Discussionmentioning

confidence: 99%

“…[25] In a recent study carried out by Wu et al (2017) diminution in Apo A1 individually led to a 97% increased risk of new T2DM over 4 years among urban Chinese community based population who were healthy and without any risk factor for T2DM. [10] However, in a Turkish sample population elevated Apo A1 levels individually predicted the incidence of T2DM with top tertile of serum Apo A1 approximately doubled the possibility of T2DM when compared with low tertile. [26] The present study demonstrated a significant increase in Apo B values in T2DM patients as compared to healthy controls.…”

Section: Discussionmentioning

confidence: 99%

“…[9] However, there are inconsistent reports on the role of Apo A and Apo B in in the development of T2DM. [10,11] Better understanding and introduction of these parameters in the lipid profile can be beneficial in prediction of risk factors, along with the improvement in lipid lowering treatment and can pave way for new therapeutic strategies. Therefore, keeping in mind the above mentioned facts the present study was designed to estimate Apo A and Apo B levels along with standard lipid profile in patients with T2DM in a tertiary care centre in north India.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Apolipoprotein A and Apolipoprotein B Levels Along With Standard Lipid Profile in Type II Diabetes Mellitus Patients in a Tertiary Care Centre in Sub Himalayan Region

Jamwal¹,

Yadav²,

Malik³

2018

AIMDR

View full text Add to dashboard Cite

Background: Apolipoprotein A (Apo A) and apolipoprotein B (Apo B) are the key structural components of high density lipoprotein (HDL) particles and atherogenic lipoproteins respectively. The present study was designed to estimate and investigate the role of Apo A and Apo B levels along with standard lipid profile in patients with type 2 diabetes mellitus (T2DM). Methods: The study was carried out on 200 subjects viz. 100 healthy controls and 100 T2DM cases. Whole blood sample was utilized for glycosylated hemoglobin (HbA1c) and serum obtained was analyzed for quantitative estimation of total cholesterol, triglycerides, low density lipoprotein (LDL), HDL, Apo A and Apo B by automated chemistry analyzer. Results: A significant increase (p < 0.005) was observed in the mean HbA1c, cholesterol, triglycerides, LDL and Apo B levels in patients with T2DM as compared to healthy controls. On the contrary, a significant decrease (p < 0.005) was witnessed in the mean HDL and Apo A values of T2DM patients as compared to healthy controls. A positive correlation was seen between HbA1c and total cholesterol (r = 0.427); HbA1c and triglyceride levels (r = 0.281); HbA1c and LDL (r = 0.399); HbA1c and Apo B (r = 0.403). However, a negative correlation was observed between HbA1c and HDL (r = -0.337); HbA1c and Apo A (r = -0.426). Conclusion: There is a high prevalence of dyslipidemia with poorly controlled HbA1c in T2DM patients. Apo A and Apo B assays should be incorporated in the standard lipid profile, for better risk prediction in diabetics and to curtail the risk of future cardiovascular mortality.

show abstract

“…Apolipoprotein A1 (APOA1), one type of apolipoprotein A family, is a primary protein component of highdensity lipoprotein (HDL) (7), and plays a role in reverse cholesterol transport that initiates multiple cellular pathways by binding to its receptor ABCA1 (8). Wu, X et al (9) reported that down-expressed APOA1 improves risk prediction of Type-2 diabetes mellitus. Tuft Stavnes, H et al reported that mRNA expression of APOA1 is a marker of longer survival in ovarian serous carcinoma effusions (10).…”

Section: Introductionmentioning

confidence: 99%

Protective Role of Panax Notoginseng Saponins in Hydrocortisone-Induced Injury in HBMECs by Promoting APOA1 Expression

Jin

Yan

Song

et al. 2020

Preprint

View full text Add to dashboard Cite

Background To evaluate the protective effect and underlying mechanism of panax notoginseng saponins (PNS) on hydrocortisone (HC)-induced injury in human bone microvascular endothelial cells (HBMECs).HBMECs were isolated from femoral heads resected in total hip arthroplasty and identified by morphology and immunofluorescence. Methods HBMECs were injured by hydrocortisone (HC), treated with PNS in different concentrations, and transfected with APOA1 or siAPOA1 to explore the role of APOA1 in the process where PNS protected HC-injured HBMECs. The viability and apoptotic rate were determined by CCK-8 and flow cytometry assays, respectively. The migration and tube length of HBMECs were evaluated by wound healing and tube formation assays, respectively. The mRNA expression of APOA1 was determined by qRT-PCR. The proteins levels of APOA1, Bcl-2, Bax and Caspase-3 were determined by Western blot. Results HBMECs exhibited spindle-shaped morphology. CD31 and vWF served as positive control and CD133 served as negative control. The viability of HBMCS inhibited by HC was balanced with the lower mRNA expression of APOA1 in a dose-dependent manner. PNS reversed the inhibitory effect of HC on the mRNA expression of APOP1, cell viability, migration, tube length, and the stimulative effect of HC on apoptosis of HBMECs. APOA1 overexpression further promoted the protective effect of PNS on HC-inhibited cell viability, migration and tube length, and HC-promoted apoptosis, whereas APOA1 silencing inhibited the protective effect of PNS and further promoted the adverse effect of HC on HBMECs. Conclusion PNS can efficiently suppress HC-induced injury in HBMECs, which may be associated with over-expressed APOA1.

show abstract

Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus

Cited by 30 publications

References 36 publications

Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol

Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol

Apolipoprotein A and Apolipoprotein B Levels Along With Standard Lipid Profile in Type II Diabetes Mellitus Patients in a Tertiary Care Centre in Sub Himalayan Region

Protective Role of Panax Notoginseng Saponins in Hydrocortisone-Induced Injury in HBMECs by Promoting APOA1 Expression

Contact Info

Product

Resources

About